{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T12:53:03Z","timestamp":1787662383348,"version":"build-2736575974"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,16]],"date-time":"2024-10-16T00:00:00Z","timestamp":1729036800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,10,16]],"date-time":"2024-10-16T00:00:00Z","timestamp":1729036800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Guangdong Regional Joint Fund","award":["2022A1515110941"],"award-info":[{"award-number":["2022A1515110941"]}]},{"DOI":"10.13039\/501100021171","name":"Basic and Applied Basic Research Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2023A04J1196"],"award-info":[{"award-number":["2023A04J1196"]}],"id":[{"id":"10.13039\/501100021171","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Guangzhou Basic and Applied Basic Research","award":["2024A03J1228"],"award-info":[{"award-number":["2024A03J1228"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82271267"],"award-info":[{"award-number":["82271267"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Key Realm R&D Program of Guangdong Province","award":["2018B030337001"],"award-info":[{"award-number":["2018B030337001"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["EJNMMI radiopharm. chem."],"DOI":"10.1186\/s41181-024-00301-y","type":"journal-article","created":{"date-parts":[[2024,10,16]],"date-time":"2024-10-16T10:02:01Z","timestamp":1729072921000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["First-in-human study of D6-[18F]FP-(+)-DTBZ, a novel VMAT2 tracer: whole-body biodistribution and brain PET comparison with [18F]FP-(+)-DTBZ (AV-133)"],"prefix":"10.1186","volume":"9","author":[{"given":"Ruiyue","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinhua","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianmin","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingwen","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siran","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaoyu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl","family":"Ploessl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Alexoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hank F.","family":"Kung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1997-5687","authenticated-orcid":false,"given":"Xinlu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,16]]},"reference":[{"issue":"2","key":"301_CR1","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1002\/mds.20733","volume":"21","author":"R Albin","year":"2006","unstructured":"Albin R, Koeppe R. Rapid loss of striatal VMAT2 binding associated with onset of Lewy body dementia. Mov Disord. 2006;21(2):287\u20138. https:\/\/doi.org\/10.1002\/mds.20733.","journal-title":"Mov Disord"},{"issue":"16","key":"301_CR2","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1212\/WNL.0b013e3181a187dd","volume":"72","author":"R Albin","year":"2009","unstructured":"Albin R, Koeppe R, Wernette K, Zhuang W, Nichols T, Kilbourn M, et al. Striatal [11C]dihydrotetrabenazine and [11C]methylphenidate binding in Tourette syndrome. Neurology. 2009;72(16):1390\u20136. https:\/\/doi.org\/10.1212\/WNL.0b013e3181a187dd.","journal-title":"Neurology"},{"issue":"4","key":"301_CR3","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1590\/0100-3984.2020.0087","volume":"54","author":"JE Arena","year":"2021","unstructured":"Arena JE, Urrutia L, Falasco G, de Leon MP, Vazquez S, Rossi M, et al. Correlation between (99m)Tc-TRODAT-1 SPECT and (18)F-FDOPA PET in patients with Parkinson\u2019s disease: a pilot study. Radiol Bras. 2021;54(4):232\u20137. https:\/\/doi.org\/10.1590\/0100-3984.2020.0087.","journal-title":"Radiol Bras"},{"issue":"6","key":"301_CR4","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1001\/jama.2019.22360","volume":"323","author":"MJ Armstrong","year":"2020","unstructured":"Armstrong MJ, Okun MS. Diagnosis and treatment of Parkinson disease: a review. JAMA. 2020;323(6):548\u201360. https:\/\/doi.org\/10.1001\/jama.2019.22360.","journal-title":"JAMA"},{"key":"301_CR5","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.0000000000207748","author":"LC Beauchamp","year":"2023","unstructured":"Beauchamp LC, Dore V, Villemagne VL, Xu S, Finkelstein D, Barnham KJ, et al. Utilizing (18)F-AV-133 VMAT2 PET imaging to monitor progressive nigrostriatal degeneration in Parkinson disease. Neurology. 2023. https:\/\/doi.org\/10.1212\/wnl.0000000000207748.","journal-title":"Neurology"},{"key":"301_CR6","first-page":"526","volume":"89","author":"M Davies","year":"1986","unstructured":"Davies M, Roberts MHT. Studies with 5-carboxamidotryptamine and ketanserin on rat brainstem neurons. Br J Pharmacol. 1986;89:526.","journal-title":"Br J Pharmacol"},{"issue":"1","key":"301_CR7","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/s41531-021-00199-2","volume":"7","author":"F Depierreux","year":"2021","unstructured":"Depierreux F, Parmentier E, Mackels L, Baquero K, Degueldre C, Balteau E, et al. Parkinson\u2019s disease multimodal imaging: F-DOPA PET, neuromelanin-sensitive and quantitative iron-sensitive MRI. NPJ Parkinsons Dis. 2021;7(1):57. https:\/\/doi.org\/10.1038\/s41531-021-00199-2.","journal-title":"NPJ Parkinsons Dis"},{"issue":"1","key":"301_CR8","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1001\/jama.2016.8655","volume":"316","author":"S Frank","year":"2016","unstructured":"Frank S, Testa CM, Stamler D, Kayson E, Davis C, Edmondson MC, et al. Effect of deutetrabenazine on chorea among patients with Huntington disease: a randomized clinical trial. JAMA. 2016;316(1):40\u201350. https:\/\/doi.org\/10.1001\/jama.2016.8655.","journal-title":"JAMA"},{"issue":"6","key":"301_CR9","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1002\/ana.410400609","volume":"40","author":"KA Frey","year":"1996","unstructured":"Frey KA, Koeppe RA, Kilbourn MR, Vander Borght TM, Albin RL, Gilman S, et al. Presynaptic monoaminergic vesicles in Parkinson\u2019s disease and normal aging. Ann Neurol. 1996;40(6):873\u201384. https:\/\/doi.org\/10.1002\/ana.410400609.","journal-title":"Ann Neurol"},{"issue":"6","key":"301_CR10","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/j.nucmedbio.2006.05.006","volume":"33","author":"R Goswami","year":"2006","unstructured":"Goswami R, Ponde D, Kung M, Hou C, Kilbourn M, Kung H. Fluoroalkyl derivatives of dihydrotetrabenazine as positron emission tomography imaging agents targeting vesicular monoamine transporters. Nucl Med Biol. 2006;33(6):685\u201394. https:\/\/doi.org\/10.1016\/j.nucmedbio.2006.05.006.","journal-title":"Nucl Med Biol"},{"issue":"4","key":"301_CR11","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1016\/j.nucmedbio.2013.12.017","volume":"41","author":"IT Hsiao","year":"2014","unstructured":"Hsiao IT, Weng YH, Lin WY, Hsieh CJ, Wey SP, Yen TC, et al. Comparison of 99mTc-TRODAT-1 SPECT and 18 F-AV-133 PET imaging in healthy controls and Parkinson\u2019s disease patients. Nucl Med Biol. 2014a;41(4):322\u20139. https:\/\/doi.org\/10.1016\/j.nucmedbio.2013.12.017.","journal-title":"Nucl Med Biol"},{"issue":"6","key":"301_CR12","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1001\/jamaneurol.2014.290","volume":"71","author":"IT Hsiao","year":"2014","unstructured":"Hsiao IT, Weng YH, Hsieh CJ, Lin WY, Wey SP, Kung MP, et al. Correlation of Parkinson disease severity and 18F-DTBZ positron emission tomography. JAMA Neurol. 2014b;71(6):758\u201366. https:\/\/doi.org\/10.1001\/jamaneurol.2014.290.","journal-title":"JAMA Neurol"},{"issue":"3","key":"301_CR13","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1080\/14737175.2017.1256205","volume":"17","author":"SH Isaacson","year":"2017","unstructured":"Isaacson SH, Fisher S, Gupta F, Hermanowicz N, Kremens DE, Lew MF, et al. Clinical utility of DaTscan\u2122 imaging in the evaluation of patients with parkinsonism: a US perspective. Expert Rev Neurother. 2017;17(3):219\u201325. https:\/\/doi.org\/10.1080\/14737175.2017.1256205.","journal-title":"Expert Rev Neurother"},{"issue":"1","key":"301_CR14","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/2191-219x-1-33","volume":"1","author":"M Jahan","year":"2011","unstructured":"Jahan M, Eriksson O, Johnstrom P, Korsgren O, Sundin A, Johansson L, et al. Decreased defluorination using the novel beta-cell imaging agent [18F]FE-DTBZ-d4 in pigs examined by PET. EJNMMI Res. 2011;1(1):33. https:\/\/doi.org\/10.1186\/2191-219x-1-33.","journal-title":"EJNMMI Res"},{"key":"301_CR15","doi-asserted-by":"publisher","first-page":"682","DOI":"10.3389\/fnins.2020.00682","volume":"14","author":"Y Kong","year":"2020","unstructured":"Kong Y, Zhou H, Feng H, Zhuang J, Wen T, Zhang C, et al. Elucidating the relationship between diabetes mellitus and Parkinson\u2019s disease using (18)F-FP-(+)-DTBZ, a positron-emission tomography probe for vesicular monoamine transporter 2. Front Neurosci. 2020;14:682. https:\/\/doi.org\/10.3389\/fnins.2020.00682.","journal-title":"Front Neurosci"},{"issue":"9","key":"301_CR16","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.2967\/jnumed.110.078196","volume":"51","author":"KJ Lin","year":"2010","unstructured":"Lin KJ, Weng YH, Wey SP, Hsiao IT, Lu CS, Skovronsky D, et al. Whole-body biodistribution and radiation dosimetry of 18F-FP-(+)-DTBZ (18F-AV-133): a novel vesicular monoamine transporter 2 imaging agent. J Nucl Med. 2010;51(9):1480\u20135. https:\/\/doi.org\/10.2967\/jnumed.110.078196.","journal-title":"J Nucl Med"},{"key":"301_CR17","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.nucmedbio.2017.11.009","volume":"57","author":"F Liu","year":"2018","unstructured":"Liu F, Choi SR, Zha Z, Ploessl K, Zhu L, Kung HF. Deuterated 18F-9-O-hexadeutero-3-fluoropropoxyl-(+)-dihydrotetrabenazine (D6-FP-(+)-DTBZ): a vesicular monoamine transporter 2 (VMAT2) imaging agent. Nucl Med Biol. 2018;57:42\u20139. https:\/\/doi.org\/10.1016\/j.nucmedbio.2017.11.009.","journal-title":"Nucl Med Biol"},{"issue":"5","key":"301_CR18","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1002\/mds.29769","volume":"39","author":"JH Ma","year":"2024","unstructured":"Ma JH, Dong C, Qiao HW, Barret O, Tamagnan GD, Mao W, et al. Striatal and extrastriatal monoaminergic disruption in progressive supranuclear palsy. Mov Disord off J Mov Disord Soc. 2024;39(5):847\u201354. https:\/\/doi.org\/10.1002\/mds.29769.","journal-title":"Mov Disord off J Mov Disord Soc"},{"issue":"5","key":"301_CR19","doi-asserted-by":"publisher","first-page":"774","DOI":"10.2967\/jnumed.108.061283","volume":"50","author":"I Madar","year":"2009","unstructured":"Madar I, Huang Y, Ravert H, Dalrymple SL, Davidson NE, Isaacs JT, et al. Detection and quantification of the evolution dynamics of apoptosis using the PET voltage sensor 18F-fluorobenzyl triphenyl phosphonium. J Nucl Med. 2009;50(5):774\u201380. https:\/\/doi.org\/10.2967\/jnumed.108.061283.","journal-title":"J Nucl Med"},{"issue":"2","key":"301_CR20","first-page":"250","volume":"15","author":"R Mehvar","year":"1987","unstructured":"Mehvar R, Jamali F, Watson MW, Skelton D. Pharmacokinetics of tetrabenazine and its major metabolite in man and rat. Bioavailability and dose dependency studies. Drug Metab Dispos. 1987;15(2):250\u20135.","journal-title":"Drug Metab Dispos"},{"key":"301_CR21","doi-asserted-by":"publisher","first-page":"223","DOI":"10.2967\/jnumed.109.070094","volume":"51","author":"N Okamura","year":"2010","unstructured":"Okamura N, Villemagne V, Drago J, Pejoska S, Dhamija R, Mulligan R, et al. In vivo measurement of vesicular monoamine transporter type 2 density in Parkinson disease with 18F-AV-133. J Nucl Med. 2010;51:223\u20138. https:\/\/doi.org\/10.2967\/jnumed.109.070094.","journal-title":"J Nucl Med"},{"issue":"11","key":"301_CR22","first-page":"1769","volume":"47","author":"DM Raffel","year":"2006","unstructured":"Raffel DM, Koeppe RA, Little R, Wang CN, Liu S, Junck L, et al. PET measurement of cardiac and nigrostriatal denervation in Parkinsonian syndromes. J Nucl Med off Publ Soc Nucl Med. 2006;47(11):1769\u201377.","journal-title":"J Nucl Med off Publ Soc Nucl Med"},{"issue":"11","key":"301_CR23","first-page":"647","volume":"103","author":"K Renwick","year":"2021","unstructured":"Renwick K. Using DaTscan to diagnose Parkinson disease. Am Fam Physician. 2021;103(11):647\u20138.","journal-title":"Am Fam Physician"},{"key":"301_CR24","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s40035-017-0076-6","volume":"6","author":"U Saeed","year":"2017","unstructured":"Saeed U, Compagnone J, Aviv RI, Strafella AP, Black SE, Lang AE, et al. Imaging biomarkers in Parkinson\u2019s disease and Parkinsonian syndromes: current and emerging concepts. Transl Neurodegener. 2017;6:8. https:\/\/doi.org\/10.1186\/s40035-017-0076-6.","journal-title":"Transl Neurodegener"},{"issue":"9","key":"301_CR25","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1097\/rlu.0000000000002664","volume":"44","author":"X Shi","year":"2019","unstructured":"Shi X, Zhang Y, Xu S, Kung HF, Qiao H, Jiang L, et al. Decreased striatal vesicular monoamine transporter type 2 correlates with the nonmotor symptoms in Parkinson disease. Clin Nucl Med. 2019;44(9):707\u201313. https:\/\/doi.org\/10.1097\/rlu.0000000000002664.","journal-title":"Clin Nucl Med"},{"issue":"10","key":"301_CR26","doi-asserted-by":"publisher","first-page":"1716","DOI":"10.1212\/01.wnl.0000161874.52302.5d","volume":"64","author":"A Siderowf","year":"2005","unstructured":"Siderowf A, Newberg A, Chou KL, Lloyd M, Colcher A, Hurtig HI, et al. [99mTc]TRODAT-1 SPECT imaging correlates with odor identification in early Parkinson disease. Neurology. 2005;64(10):1716\u201320. https:\/\/doi.org\/10.1212\/01.wnl.0000161874.52302.5d.","journal-title":"Neurology"},{"key":"301_CR27","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.parkreldis.2019.04.006","volume":"64","author":"GS Smith","year":"2019","unstructured":"Smith GS, Mills KA, Pontone GM, Anderson WS, Perepezko KM, Brasic J, et al. Effect of STN DBS on vesicular monoamine transporter 2 and glucose metabolism in Parkinson\u2019s disease. Parkinsonism Relat Disord. 2019;64:235\u201341. https:\/\/doi.org\/10.1016\/j.parkreldis.2019.04.006.","journal-title":"Parkinsonism Relat Disord"},{"issue":"1","key":"301_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1017\/s1092852917000621","volume":"23","author":"SM Stahl","year":"2018","unstructured":"Stahl SM. Mechanism of action of vesicular monoamine transporter 2 (VMAT2) inhibitors in tardive dyskinesia: reducing dopamine leads to less \u201cgo\u201d and more \u201cstop\u201d from the motor striatum for robust therapeutic effects. CNS Spectr. 2018;23(1):1\u20136. https:\/\/doi.org\/10.1017\/s1092852917000621.","journal-title":"CNS Spectr"},{"issue":"11","key":"301_CR29","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1016\/s1474-4422(11)70214-9","volume":"10","author":"AJ Stoessl","year":"2011","unstructured":"Stoessl AJ, Martin WW, McKeown MJ, Sossi V. Advances in imaging in Parkinson\u2019s disease. Lancet Neurol. 2011;10(11):987\u20131001. https:\/\/doi.org\/10.1016\/s1474-4422(11)70214-9.","journal-title":"Lancet Neurol"},{"issue":"2","key":"301_CR30","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1002\/mds.26907","volume":"32","author":"AP Strafella","year":"2017","unstructured":"Strafella AP, Bohnen NI, Perlmutter JS, Eidelberg D, Pavese N, Van Eimeren T, et al. Molecular imaging to track Parkinson\u2019s disease and atypical parkinsonisms: new imaging frontiers. Mov Disord. 2017;32(2):181\u201392. https:\/\/doi.org\/10.1002\/mds.26907.","journal-title":"Mov Disord"},{"issue":"10","key":"301_CR31","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.1038\/jcbfm.2011.63","volume":"31","author":"J Tong","year":"2011","unstructured":"Tong J, Boileau I, Furukawa Y, Chang LJ, Wilson AA, Houle S, et al. Distribution of vesicular monoamine transporter 2 protein in human brain: implications for brain imaging studies. J Cereb Blood Flow Metab. 2011;31(10):2065\u201375. https:\/\/doi.org\/10.1038\/jcbfm.2011.63.","journal-title":"J Cereb Blood Flow Metab"},{"key":"301_CR32","doi-asserted-by":"crossref","unstructured":"Valentin J. Basic anatomical and physiological data for use in radiological protection: reference values. A report of age- and gender-related differences in the anatomical and physiological characteristics of reference individuals. In: Annals of the ICRP. Vol. 32. ICRP Publication 89; 2002. p. 5\u2013265.","DOI":"10.1016\/S0146-6453(03)00002-2"},{"key":"301_CR33","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.nucmedbio.2019.07.002","volume":"72\u201373","author":"R Zhao","year":"2019","unstructured":"Zhao R, Zha Z, Yao X, Ploessl K, Choi SR, Liu F, et al. VMAT2 imaging agent, D6-[18F]FP-(+)-DTBZ: improved radiosynthesis, purification by solid-phase extraction and characterization. Nucl Med Biol. 2019;72\u201373:26\u201335. https:\/\/doi.org\/10.1016\/j.nucmedbio.2019.07.002.","journal-title":"Nucl Med Biol"}],"container-title":["EJNMMI Radiopharmacy and Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41181-024-00301-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41181-024-00301-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41181-024-00301-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,16]],"date-time":"2024-10-16T21:03:41Z","timestamp":1729112621000},"score":1,"resource":{"primary":{"URL":"https:\/\/ejnmmipharmchem.springeropen.com\/articles\/10.1186\/s41181-024-00301-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,16]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["301"],"URL":"https:\/\/doi.org\/10.1186\/s41181-024-00301-y","relation":{},"ISSN":["2365-421X"],"issn-type":[{"value":"2365-421X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,16]]},"assertion":[{"value":"27 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Clinical Research Ethics Committee of the First Affiliated Hospital of Guangzhou Medical University (ES-2021-62), and it was conducted according to the principles of the Declaration of Helsinki. Trial registration: Chinese Clinical Trial Registry, ChiCTR2200057218, Registered 16 August 2021, .","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Informed consent was obtained from all participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"David Alexoff, Karl Ploessl, and Hank F. Kung are employees of Five Eleven Pharma Inc., and Hank Kung is also the founder and board of the company, which holds the patent rights for D6-[<sup>18<\/sup>F]FP-(+)-DTBZ and related technology. Other authors have no conflicts of interest or relevant financial activities to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"71"}}